Home > Products > CD28 & FOLR1 > Recombinant Anti-CD28 x Anti-FOLR1 Bispecific Antibody (scFv-CH1/CL)

Recombinant Anti-CD28 x Anti-FOLR1 Bispecific Antibody (scFv-CH1/CL)  (BSCC-060)

Recombinant Anti-CD28 x Anti-FOLR1 Bispecific Antibody (scFv-CH1/CL) is designed to be expressed as two chains. One scFv from an anti-CD28 antibody variable domain is fused to CH1 and the other scFv from an anti-FOLR1 antibody variable domain fused to CL, or vice versa. And the CH1 and CL domains are linked covalently via a natural disulfide bond. This BsAb can retarget T cells to tumor cells. It is designed for the research of Ovarian cancer; Solid tumors therapy.

Specifications

Targets
CD28 & FOLR1
Type
scFv-based Bispecific Fragments
Species Reactivity
Human
Target 1
CD28
Host Animal 1
Mouse
Target 2
FOLR1
Host Animal 2
Mouse
Application
FuncS; Promising therapeutic agent
Related Disease
Ovarian cancer; Solid tumors

Targets

Target 1
CD28
Gene ID
UniProt ID
Alternative Names
CD28; CD28 molecule; Cluster of Differentiation 28; Tp44; T-cell-specific surface glycoprotein CD28; CD28 antigen
Target 2
FOLR1
Gene ID
UniProt ID
Alternative Names
FOLR1; folate receptor 1 (adult); folate receptor 1; FBP; FOLR; folate receptor alpha; FR-alpha; KB cells FBP; folate binding protein; folate receptor, adult; adult folate-binding protein; ovarian tumor-associated antigen MOv18

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD28 x Anti-FOLR1 Bispecific Antibody (scFv-CH1/CL) (BSCC-060). Click the button below to contact us or submit your feedback about this product.

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY
Related products of "CD28 & FOLR1"
See other bsAb targets related to "CD28"

See other bsAb targets related to "FOLR1"

Online Inquiry

24x7 Service quality
USA

Tel:
Fax:
Email:

UK

Tel:
Email:

Germany

Tel:
Email: